If you’re experiencing night sweats, consider Evamist.
Evamist has been approved for the treatment of moderate to severe vasomotor symptoms due to menopause.
Episodes of excessive nighttime sweating are considered a type of hot flash or vasomotor symptom. They occur during sleep hours, may be strong enough to disrupt normal sleep patterns and are generally considered a moderate to severe type of hot flash.1
If you experience night sweats due to menopause, talk with your healthcare provider. He or she can recommend treatment options that may help, including Evamist® (estradiol transdermal spray).
When Evamist is applied at 8 a.m., the medicine level in your system peaks between 2 and 6 a.m., during typical sleep hours.2
Plus, a prescription for Evamist provides dosing flexibility. You may start with the lowest dose – one spray – and still have the option of applying a higher dose – two or three sprays – according to your doctor’s instruction. This helps ensure you experience the potential benefits of the medication at the lowest effective dose.
A clinical study evaluated Evamist for the treatment of moderate to severe vasomotor symptoms due to menopause in 454 women. The study demonstrated that Evamist significantly reduced how often the women experienced hot flashes, as well as the severity of the hot flashes.3
If you’re experiencing moderate to severe hot flashes, including night sweats, talk to your doctor to find out if Evamist® (estradiol transdermal spray) is right for you.
For more information, refer to the Patient Information section of the full Prescribing Information or ask your healthcare provider or pharmacist.
- Utian W. (2005) Menopause Practice: a Clinician’s Guide 2nd edition. Cleveland, OH: North American Menopause Society.
- Buster JE, Koltoun WD, Pascual MLG, et al. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111:1343-51.
- Greene JG. Constructing a standard climacteric scale. Maturitas. 1998 May 20;29 (1):25-31.
- Evamist® (estradiol transdermal spray) Prescribing Information, Perrigo, January 2015.